ONIVYDE, also known by its generic name irinotecan liposome injection, is a chemotherapy medication used in the treatment of cancer. Specifically, it is approved for use in patients with metastatic pancreatic cancer following progression after gemcitabine-based therapy. ONIVYDE works by encapsulating the irinotecan drug in liposomes, which are tiny spherical vesicles. This encapsulation helps in the slow release of the drug, allowing for a more targeted and sustained attack on cancer cells while potentially reducing some of the side effects associated with traditional chemotherapy. It is administered intravenously and is often used in combination with other medications to enhance its efficacy against cancer cells. As with any chemotherapy drug, ONIVYDE can have significant side effects, and its use is carefully considered by healthcare professionals based on the individual patient's condition and response to treatment.